Solid Biosciences (SLDB) Equity Ratio (2017 - 2026)

Solid Biosciences has disclosed Equity Ratio across 10 years of filings, most recently posting 0.88 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.88, up 3.32% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.88 (up 3.32% YoY), and the FY2025 annual result was 0.77, up 6.41% from the prior year.
• Equity Ratio came in at 0.88 for Q1 2026 at Solid Biosciences, up from 0.77 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.89 in Q1 2022 to a low of 0.73 in Q4 2024.
• The 5-year median for Equity Ratio is 0.8 (2023), against an average of 0.81.
• Across the five-year window, Equity Ratio decreased 13.42% in 2022 and grew 6.41% in 2025, its largest moves.
• Solid Biosciences' Equity Ratio stood at 0.81 in 2022, then slipped by 5.71% to 0.77 in 2023, then slipped by 5.13% to 0.73 in 2024, then increased by 6.41% to 0.77 in 2025, then increased by 14.29% to 0.88 in 2026.
• The last three Equity Ratio figures came in at 0.88 (Q1 2026), 0.77 (Q4 2025), and 0.8 (Q3 2025), per Business Quant data.